iSpecimen approves AI deal as iSpecimen stock faces reverse split vote

Published on 10/16/2026 at 01:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Four proposals passed on October 9, 2026, including the Foldlab AI deal. iSpecimen stock faces a 1-for-10 to 1-for-100 vote October 30.

Shareholder decisions shape next steps

On October 9, 2026, 791,600 votes supported the Foldlab AI asset acquisition.
Revenue was USD 152,000 in Q2 2026, down 85.60 percent year over year.
The reverse split vote is scheduled for October 30, 2026, at a 1-for-10 to 1-for-100 ratio.

ISPC, US45032V3069, Illustration mit AI erstellt.

iSpecimen (ISIN US45032V3069) won approval for its Foldlab AI asset acquisition with 791,600 votes for at the October 9, 2026, special meeting, according to StockTitan. The same meeting approved financing-related share issuances, while voting on a proposed reverse split was adjourned to October 30, 2026.

What does the vote mean for dilution?

The financing approvals create room for future issuance that may exceed 19.99 percent of common shares outstanding. Another approved measure permits conversion or exercise prices reflecting a discount of up to 80 percent from the applicable lowest volume weighted average price, according to StockTitan.

For operating context, iSpecimen reported USD 152,000 of revenue in the second quarter of 2026, down 85.60 percent year over year, while net loss was USD 1.36 million, according to ToAlpha and TradingView. The financing votes therefore arrive alongside a sharply smaller quarterly revenue base.

Three decisions in the record

On August 7, 2026, iSpecimen announced the closing of a USD 5 million public offering. On September 4, 2026, its proxy materials set out a proposed reverse split ranging from 1-for-10 to 1-for-100. On October 9, 2026, stockholders approved the Foldlab AI asset acquisition with 791,600 votes for, as reported by StockTitan.

Next dates for shareholders

Online and phone voting on the remaining reverse split proposal closes at 11:59 p.m. Eastern Time on October 29, 2026. The adjourned virtual meeting is scheduled for October 30, 2026, at 10:00 a.m. Eastern Time, according to StockTitan.

Financing meets platform execution

iSpecimen describes its marketplace as a platform linking researchers with patients, specimens and data, according to the company's investor overview at iSpecimen. The next shareholder vote will determine whether the proposed reverse split joins the already approved financing and acquisition measures.